Browsing by Yonsei Author : Cho, Byoung Chul

eperson profile image
Name:
Cho, Byoung Chul [조병철]
orcid http://orcid.org/0000-0002-5562-270X
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7401747804)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 283

This table browses all dspace content
Issue DateTitleJournal Title
2022Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
2022First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors INVESTIGATIONAL NEW DRUGS
2022Lazertinib: on the Way to Its Throne YONSEI MEDICAL JOURNAL
2022Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer CLINICAL LUNG CANCER
2022Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1 BIOMEDICINE & PHARMACOTHERAPY
2022DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy EXPERIMENTAL AND MOLECULAR MEDICINE
2022Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)CLINICAL CANCER RESEARCH
2022A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancerEXPERT OPINION ON INVESTIGATIONAL DRUGS
2022Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung CancerCLINICAL LUNG CANCER
2022Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC JTO Clinical and Research Reports
2022Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyLANCET ONCOLOGY
2022Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation THERANOSTICS
2022Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter TrialJOURNAL OF THORACIC ONCOLOGY
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2022A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors JOURNAL OF THORACIC ONCOLOGY
2022Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors CLINICAL CANCER RESEARCH
2022Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer JOURNAL OF CLINICAL ONCOLOGY
2022Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice CLINICAL CANCER RESEARCH
2022Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice CURRENT ONCOLOGY
2022Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapyRADIOTHERAPY AND ONCOLOGY
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2022MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerFUTURE ONCOLOGY
2022A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialANNALS OF ONCOLOGY
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung CancerCANCER RESEARCH
2022Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLCCANCER DISCOVERY
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2021SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2021Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)CLINICAL LUNG CANCER
2021Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyJOURNAL OF CLINICAL ONCOLOGY
2021Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study JOURNAL OF THORACIC ONCOLOGY
2021Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCJOURNAL OF THORACIC ONCOLOGY
2021Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies JTO Clinical and Research Reports
2021Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study JOURNAL OF THORACIC ONCOLOGY
2021Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study JOURNAL OF THORACIC ONCOLOGY
2021Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancerLUNG CANCER
2021The promise of bispecific antibodies: Clinical applications and challengesCANCER TREATMENT REVIEWS
2021Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyLANCET
2021Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial CLINICAL CANCER RESEARCH
2021Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma CLINICAL CANCER RESEARCH
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2021Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors JTO Clinical and Research Reports
2021A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma CANCER MEDICINE
2021Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC) CLINICAL LUNG CANCER
2021Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyLANCET ONCOLOGY
2021Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study CANCERS
2021Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib JTO Clinical and Research Reports
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2021Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 studyCANCER

Browse

Links